(Q52072205)

English

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

scientific article published in November 2000

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

secondary progressive multiple sclerosis

0 references

multiple sclerosis

0 references

magnetic resonance imaging

0 references

Gareth J. Barker

14

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

author name string

P D Molyneux

1

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

L Kappos

2

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

C Polman

3

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

C Pozzilli

4

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

F Barkhof

5

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

M Filippi

6

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

T Yousry

7

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

D Hahn

8

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

K Wagner

9

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

M Ghazi

10

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

K Beckmann

11

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

F Dahlke

12

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

N Losseff

13

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

A J Thompson

15

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

D H Miller

16

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

language of work or name

0 references

publication date

1 November 2000

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

123 ( Pt 11)

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

2256-2263

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

A reproducible repositioning method for serial magnetic resonance imaging studies of the brain in treatment trials for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

One year follow up study of primary and transitional progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2F123.11.2256

21 January 2018

Identifiers

10.1093/BRAIN/123.11.2256

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/11050025

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52072205&oldid=1708002872"